Over the past six months (March 2026 - September 2026), Protara Therapeutics experienced several stock-related events. On September 21, 2026, the company announced positive interim results from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric lymphatic malformations and positive updated 12-month data demonstrating durable responses in the fully enrolled BCG-Naïve cohort of the Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC. The stock surged on September 9, 2026, due to reported superior efficacy of its bladder cancer cell therapy. The company participated in the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. On August 13, 2026, Janus Henderson Group reported an 8.4% stake, and on August 11, 2026, the company released its Second Quarter 2026 financial results. Co-founder Jesse Shefferman filed an Intent To Sell Form for 216,000 shares on June 29, 2026, and Chief Medical Officer Leonardo Viana Nicacio resigned on June 26, 2026. The company presented at the TD Cowen 7th Annual Oncology Innovation Summit on May 20, 2026, and hosted a virtual investor webinar on TARA-002 for lymphatic malformations on May 18, 2026. Positive updated 12-month data from the Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC was announced on May 15, 2026, followed by First Quarter 2026 financial results on May 13, 2026. Updated, interim 12-month data from the Phase 2 ADVANCED-2 trial of TARA-002 was presented at the American Urological Association Annual Meeting on April 27, 2026. The company announced its Fourth Quarter and Full Year 2025 financial results on March 10, 2026. Finally, on February 24, 2026, the stock experienced its largest daily move in the past year, decreasing by 26.4%.
